Skip to main content
Top
Published in: Reactions Weekly 1/2024

01-03-2024 | Abatacept | Case report

Multiple drugs

Lack of efficacy

Published in: Reactions Weekly | Issue 1/2024

Login to get access

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literature
go back to reference Shelikhova L, et al. Post-Transplant Cyclophosphamide, Abatacept, and Vedolizumab to Prevent Graft-Versus-Host Disease after Hematopoietic Stem Cells Transplantation from Haploidentical Donors in Children with Acute Leukemia: Results of a Prospective Trial. Blood 142 (Suppl. 1): 3555, Nov 2023. Available from: URL: https://dx.doi.org/10.1182/blood-2023-182895 [abstract] Shelikhova L, et al. Post-Transplant Cyclophosphamide, Abatacept, and Vedolizumab to Prevent Graft-Versus-Host Disease after Hematopoietic Stem Cells Transplantation from Haploidentical Donors in Children with Acute Leukemia: Results of a Prospective Trial. Blood 142 (Suppl. 1): 3555, Nov 2023. Available from: URL: https://​dx.​doi.​org/​10.​1182/​blood-2023-182895 [abstract]
Metadata
Title
Multiple drugs
Lack of efficacy
Publication date
01-03-2024
Publisher
Springer International Publishing
Published in
Reactions Weekly / Issue 1/2024
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-54173-5

Other articles of this Issue 1/2024

Reactions Weekly 1/2024 Go to the issue

Case report

Benzocaine

Case report

Multiple drugs

Case report

Anastrozole

Case report

Dipyrone

Case report

Antineoplastics